Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Vertiv Holdings Co — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Vertiv Holdings Co trades at $218.49 (market cap $91.35B). The key difference: Vertiv Holdings Co is far larger — about 18.7× Travere Therapeutics Inc. Common Stock's market cap, and Vertiv Holdings Co pays a 0.11% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vertiv Holdings Co for 40 Days on average.
| TVTX | VRT | |
|---|---|---|
Market Cap | $4.88B | $91.35B |
Volume | 1,668,577 | 4,805,860 |
Sector | Health | Industrials |
52-Week High | $67.52 | $376.23 |
52-Week Low | $26.79 | $149.83 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $5.01B | $91.58B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Vertiv (VRT) trades at $237.29, down 0.86% on the day, amid a bearish technical signal. The stock exhibits strong fundamentals with revenue growth from $10.23B in 2025 to $11.5B projected for 2026 and a robust net income margin of 15.09%. Recent earnings have consistently beaten estimates, and analyst sentiment remains overwhelmingly positive with a 90.48% buy rating and a consensus price target of $366.12. However, technical indicators show selling pressure, with the price near support at $237.
The outlook for VRT is favorable due to its strategic position in the AI data center infrastructure market, driving revenue and margin expansion. Key risks include execution of growth initiatives, competitive pressures, and market volatility. The significant upside to the analyst target presents a potential opportunity, but investors should weigh the strong fundamentals against the current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
